Publications:119
Video Visit Available
Accepting New Patients
- Mount Sinai Doctors
- Treats Adults
- Video Visit Available
- Accepting New Patients
Joshua Richter, MD
Internal Medicine, Hematology-Oncology, Cancer (Oncology)
About Me
Joshua Richter, MD, is Associate Professor of Medicine in The Tisch Cancer Institute, Division of Hematology and Medical Oncology. He is the director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai. Dr. Richter treats patients with plasma cell dyscrasias, including multiple myeloma and related diseases such as AL amyloidosis, plasma cell leukemia and Waldenstrom’s Macroglobulinemia. Dr. Richter has extensive experience with clinical trials focused on novel therapies, including antibody therapy and immunotherapy for a precision medicine approach. He has published extensively on these topics and has been invited to speak regionally, nationally, and also internationally. He has been published in journals such as the New England Journal of Medicine, Blood and the Journal of Clinical Oncology.
The state of Florida requires out-of-state professionals who are registered to provide telehealth services to display a hyperlink to the Florida Department of Health telehealth web page. This allows Florida patients who are receiving medical care by telehealth to confirm the provider’s licensure and Florida registration.
Language
English
Position
ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Hospital Affiliations
- Mount Sinai Beth Israel
- Mount Sinai Morningside
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
Clinical Focus
- Amyloidosis
- Hematologic Malignancies
- Monoclonal Gammopathy of Uncertain Significance (MGUS)
- Multiple Myeloma
- Smoldering Myeloma
- Waldenström's Macroglobulinemia
Education
MD, New York Medical College
Internship, Internal Medicine
St. Vincent's Hospital & Medical Center
Residency, Internal Medicine
St. Vincent's Hospital & Medical Center
Fellowship, Hematology & Oncology
Yale New Haven Hospital
Certifications
American Board of Internal Medicine
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information. Patients with Anthem Blue Cross Blue Shield (formerly known as Empire) please click here for more information. Patients with Molina insurance should click here for more information. Mount Sinai’s contracts with Anthem and Molina expired on December 31.
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Magnacare-Health Care
- Medicare - NJ
- Medicare - NY
- Metroplus
- Multiplan PHCS
- NJ Medicaid
- NY Medicaid
- Oscar
- Oxford - Freedom and Liberty
- United Health Care - Commercial
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VNSNY Select Health Medicaid
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Selected Publications
- Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression. Junia Vieira dos Santos, David T. Melnekoff, Adolfo Aleman, Tarek H. Mouhieddine, Rocio Montes de Oca, Feng Wang, Sridevi Rajeeve, Sherry Bhalla, Oliver Van Oekelen, Bhaskar Upadhyaya, Yogita Ghodke-Puranik, Violetta Leshchenko, Seunghee Kim-Schulze, Adeeb Rahman, Shaked Afik, Hadas Lewinsky, Vicki Plaks, Santiago Thibaud, Hearn Jay Cho, Joshua Richter, Cesar Rodriguez, Larysa Sanchez, Adriana Rossi, Shambavi Richard, Ajai Chari, Deepu Madduri, Sundar Jagannath, Samir Parekh, Alessandro Laganà. Blood advances
- Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses. Hans C. Lee, Jeffrey A. Zonder, Madhav V. Dhodapkar, Sundar Jagannath, James E. Hoffman, Attaya Suvannasankha, Mansi R. Shah, Suzanne Lentzsch, Rachid Baz, Joseph J. Maly, Swathi Namburi, Matthew J. Pianko, Jing Christine Ye, Ka Lung Wu, Rebecca Silbermann, Chang Ki Min, Marie Christiane Vekemans, Markus Munder, Ja Min Byun, Joaquín Martínez-Lopez, Michelle DeVeaux, Tito Roccia, Dhruti Chokshi, Megan Seraphin, Kate Knorr, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Naresh Bumma, Joshua Richter. Clinical Lymphoma, Myeloma and Leukemia
- Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab. Shaji Kumar, María Victoria Mateos, Jing Christine Ye, Shebli Atrash, Hila Magen, Hang Quach, Michael P. Chu, Suzanne Trudel, Joshua Richter, Paula Rodríguez-Otero, Hun Chuah, Moshe Gatt, Eva Medvedova, Shahzad Raza, Dok Hyun Yoon, Tadao Ishida, Jeffrey V. Matous, Laura Rosiñol, Koichi Onodera, Emma Scott, Christoph Heuck, Jenny Zhang, Todd Henninger, Lisa O’Rourke, Payal Thakkar, Mariacristina Festa, Lin Huang, Jiangxiu Zhou, Mikihiro Takamoto, Lixia Pei, Jiashen Lu, Nicholas Au, Maria Krevvata, Saad Z. Usmani, Yael C. Cohen. New England Journal of Medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Richter during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Stemline/Menarini
- Bristol-Myers Squibb
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Karyopharm Inc.
- AbbVie, Inc.
- Forus
- Regeneron Pharmaceuticals, Inc.
- adaptive biotechnologies
- Takeda Pharmaceutical Company Limited
- antengene
- sanofi-aventis
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.